Parameter
| Biomarker | Phosphatidylcholine (PC) | Full name | Phosphatidylcholine | Molecular Type | Lipids (phospholipids) |
|---|---|---|---|---|---|
| Molecular Formula | Varies by subtype (EPA: C₂₀H₃₀O₂; DHA: C₂₂H₃₂O₂; Linoleic acid: C₁₈H₃₂O₂) Varies by fatty acid chain (e.g., PC 36:3: C₄₂H₈₀NO₈P) C₃H₅(OOC-R)₃ (R = fatty acid chain, e.g., palmitic acid: C₁₆H₃₂O₂) | Molecular Weight | Varies by fatty acid chain (e.g., PC 36:3: ~758 Da) | Core Functional Dimensions | Membrane structure maintenance, lipoprotein assembly |
| Disease | Metabolic Associated Fatty Liver Disease (MASLD) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Liver tissue (lipidomic mass spectrometry), plasma (lipidomic mass spectrometry) | ||
| Pathobiological Mechanisms | Decreased PC synthesis in liver tissue and increased plasma PC isoforms, such as PC (36:3), affect VLDL assembly and secretion | ||||
| Clinical Availability Status | Research Phase | ||||
| Notes and Dynamics | PC analogues have shown anti-steatosis effects in animal models and are of research value | ||||